Reference

Peptide half-life chart

A sourced half-life figure for every tracked compound — 15 of 71 carry one. Everywhere else, this table states plainly that no sourced figure has been identified rather than showing a number nothing backs.

Topic: Reading published half-life figures against their sources

Compounds covered: All 71 tracked peptide profiles

Reading time: 4–6 minutes, or a lookup

On this page

1.How this table is sourced
2.Half-life by compound
3.Related pages

How this table is sourced

Every Prof. Peptide profile publishes a half-life figure in its Quick Facts summary. This table shows that figure only where a source supports it — 15 of 71 compounds. For the other 56, no number appears here at all, for two different reasons:

Sourcedthe profile’s reference list contains a source — an FDA label, a published pharmacokinetic study, or a figure reconciled against the Prof. Peptide app’s own cited dataset, itself confirmed against the compound’s own profile — that supports the figure. The citation is printed beside it, with a link. 15 compounds (2 more held back pending reconciliation — see below).
No sourced figurethe profile publishes a figure, but nothing in its own citations supports it. This table does not repeat that figure — it states the absence instead. Sourcing these (17 compounds) is a research pass of its own, tracked separately from this page.
Not publishedthe profile states an honest absence rather than a figure — a compound this poorly characterized in humans that no number is published at all (39 compounds). That absence is itself the profile’s answer, reproduced verbatim below.

A blend or a compound with more than one form — CJC-1295’s no-DAC and DAC forms, for instance — can carry different sourcing per component. Where that happens, each component is shown on its own line, sourced or not, rather than one status standing for the whole row.

Two compounds the underlying dataset marks sourced are shown here as having no sourced figure instead: cagrilintide, whose profile carries no citation for its half-life at all, and tesamorelin, whose profile reads the same FDA label the dataset cites and states a different number from it (11 and 8 minutes, against the dataset’s 26–38 minutes). A figure renders on this chart only where the dataset and the compound’s own profile agree it is sourced — both are held back pending reconciliation.

Half-life by compound

Metabolic & GLP-1

Compound	Published figure	Status	Source
5-Amino-1MQ	Not well characterized in humans	Not published	—
Adipotide	Not characterized in humans	Not published	—
AOD-9604	No sourced figure identified.	No sourced figure	—
AOD-9604 + MOTS-c	Not well characterized for either component	Not published	—
Cagrilintide	No sourced figure identified.	No sourced figure	—
CagriSema	Cagrilintide: No sourced figure identified. Semaglutide: ~7 days	Sourced	— OZEMPIC (semaglutide) prescribing information — "the long half-life of OZEMPIC of approximately 1 week". Read 2026-09-21.
HGH Fragment 176-191	Not characterized in humans for the bare fragment — no published pharmacokinetic study was located	Not published	—
Mazdutide	Long-acting — supports once-weekly dosing	Not published	—
Metabolic Blend (NAD+ / MOTS-c / 5-Amino-1MQ)	Varies by component; not characterized for the combination	Not published	—
MOTS-c	Not well characterized in humans; dosed once daily by convention	Not published	—
Retatrutide	~6 days	Sourced	Half-life ~6 days (investigational, not FDA-approved). Source: Phase 2 clinical data — Jastreboff et al., NEJM 2023; Coskun et al., Cell Metab 2022.
Semaglutide	~168 hours (~7 days)	Sourced	Half-life ~1 week. Source: FDA prescribing information (Wegovy / Ozempic).
Semaglutide + BPC-157	Semaglutide: ~7 days BPC-157: No sourced figure identified.	Sourced	OZEMPIC (semaglutide) prescribing information — "the long half-life of OZEMPIC of approximately 1 week". Read 2026-09-21. —
Survodutide	Long-acting — supports once-weekly dosing	Not published	—
Tirzepatide	~5 days (~120 hours)	Sourced	Half-life ~5 days, Tmax ~24h. Source: FDA prescribing information (Mounjaro).
Tirzepatide + BPC-157	Tirzepatide: ~5 days BPC-157: No sourced figure identified.	Sourced	MOUNJARO (tirzepatide) prescribing information — "the half-life of tirzepatide of approximately 5 days". Read 2026-09-21. —

Recovery & Tissue Repair

Compound	Published figure	Status	Source
BPC-157	No sourced figure identified.	No sourced figure	—
Cibinetide (ARA-290)	Short peptide half-life; no verified human PK value	Not published	—
PDA (Pentadeca Arginate)	Not characterized in humans	Not published	—
TB-500	Multiple days (estimated from animal studies)	Not published	—
Wolverine Stack	BPC-157: No sourced figure identified. TB-500: No sourced figure identified.	No sourced figure	— —

Performance & Energy

Compound	Published figure	Status	Source
IGF-1 DES	No verified human PK — free IGF peptides clear in minutes	Not published	—
IGF-1 LR3	No sourced figure identified.	No sourced figure	—
MGF	Native MGF ~ minutes; PEG-MGF extended by pegylation, but no verified human PK	Not published	—
Follistatin	~90 minutes (injectable peptide)	Sourced	Datta-Mannan A, Yaden B, Krishnan V, et al. An engineered human follistatin variant: insights into the pharmacokinetic and pharmacodynamic relationships of a novel molecule with broad therapeutic potential. J Pharmacol Exp Ther. 2013;344(3):616-23.

Growth Hormone

Compound	Published figure	Status	Source
CJC-1295	no-DAC / Mod GRF 1-29: No sourced figure identified. with DAC: 6–8 days	Sourced	— CJC-1295 with DAC — t½ ~6–8 days (Teichman et al., JCEM 2006).
CJC-1295 (No DAC) + Ipamorelin (GH Stack)	CJC-1295 (no-DAC): No sourced figure identified. Ipamorelin: ~2 hours	Sourced	— Gobburu et al., Pharm Res 1999;16(9):1412–6 — terminal half-life 2 hours.
GHRP-2	No sourced figure identified.	No sourced figure	—
GHRP-6	No sourced figure identified.	No sourced figure	—
Hexarelin	No sourced figure identified.	No sourced figure	—
Ipamorelin	~2 hours	Sourced	Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412–6 — terminal half-life 2 hours. Read 2026-09-21.
MK-677	No sourced figure identified.	No sourced figure	—
MK-677 + Ipamorelin	MK-677: No sourced figure identified. Ipamorelin: ~2 hours	Sourced	— Gobburu et al., Pharm Res 1999;16(9):1412–6 — terminal half-life 2 hours.
Sermorelin	No sourced figure identified.	No sourced figure	—
Sermorelin + Ipamorelin	Sermorelin: No sourced figure identified. Ipamorelin: ~2 hours	Sourced	— Gobburu et al., Pharm Res 1999;16(9):1412–6 — terminal half-life 2 hours.
Tesamorelin	Egrifta WR: No sourced figure identified. Egrifta SV: No sourced figure identified.	No sourced figure	— —
Tesamorelin + Ipamorelin	Tesamorelin: ~0.18 hours Ipamorelin: ~2 hours	Sourced	EGRIFTA WR prescribing information, Clinical Pharmacology — Elimination. Re-read 2026-09-21. Gobburu et al., Pharm Res 1999;16(9):1412–6 — terminal half-life 2 hours.

Cognitive & Nootropic

Compound	Published figure	Status	Source
Adamax	Uncharacterized for Adamax; parent Semax is short (minutes)	Not published	—
Selank	Short plasma half-life; biological effects build over days	Not published	—
Semax	No sourced figure identified.	No sourced figure	—
PE-22-28	Not characterized — the published figure is a DURATION OF ACTION in mice, about 23 hours against spadin's 7, which is not a half-life	Not published	—
Semax + Selank	Very short for both components (minutes in plasma), but CNS effects last hours	Not published	—

Skin Health & Anti-Aging

Compound	Published figure	Status	Source
AHK-Cu	Not characterized — the single located source is an ex vivo/in vitro study with no pharmacokinetic measurement	Not published	—
GHK-Cu	Short plasma half-life; effects persist via gene-expression changes	Not published	—
GLOW	Not established for the blend — varies by component	Not published	—
KLOW	Not established for the blend — varies by component	Not published	—
Melanotan I (Afamelanotide)	Short in plasma; the Scenesse implant is controlled-release over ~2 months	Not published	—
Melanotan II	~hours in plasma; pigmentation effects accumulate over weeks	Not published	—
SNAP-8	Not characterized — no pharmacokinetic data published for this ingredient	Not published	—

Gut Health & Immunity

Compound	Published figure	Status	Source
KPV	No sourced figure identified.	No sourced figure	—
KPV + BPC-157	Not well characterized in humans for either component	Not published	—
LL-37	Not well characterized in humans	Not published	—
Thymosin Alpha-1	No sourced figure identified.	No sourced figure	—
VIP (Vasoactive Intestinal Peptide)	No sourced figure identified.	No sourced figure	—

Sleep & Recovery

Compound	Published figure	Status	Source
DSIP	Short plasma half-life; biological effects persist far longer	Not published	—

Longevity

Compound	Published figure	Status	Source
Epitalon	No sourced figure identified.	No sourced figure	—
Glutathione (GSH)	Not well characterized — rapidly metabolized, varies by route	Not published	—
NAD+	Short plasma half-life; cellular NAD+ pools persist via downstream conversion	Not published	—
FOXO4-DRI	Not characterized in humans — the retro-inverso design is intended to resist protease degradation, but no human pharmacokinetic data exist	Not published	—
SS-31 (Elamipretide)	Not established in the public research literature	Not published	—

Bioregulators

Compound	Published figure	Status	Source
Pinealon	Not well characterized	Not published	—
Thymogen	Not well characterized	Not published	—
Cortagen	Not characterized	Not published	—
Cardiogen	Not well characterized	Not published	—
Cartalax	Not characterized	Not published	—
Crystagen	Not characterized	Not published	—
Thymalin	Not characterized — and not a single figure in principle, since this is a mixture rather than one molecule	Not published	—

Sexual Health

Compound	Published figure	Status	Source
Kisspeptin	No sourced figure identified.	No sourced figure	—
Oxytocin	Short-acting; reconstituted oxytocin is comparatively unstable — refrigerate and use within a shorter window than a typical peptide	Not published	—
PT-141	~2.7 hours; effects last 4–6 hours	Sourced	Vyleesi (bremelanotide injection) FDA Prescribing Information, 2019.
PT-141 + Oxytocin	PT-141: No sourced figure identified. Oxytocin: 0.02–0.1 hours	Sourced	— Pitocin (oxytocin injection) prescribing information — "Oxytocin has a plasma half-life of about 1 to 6 minutes which is decreased in late pregnancy and during lactation." Read 2026-09-21.

Frequently asked questions

What is a peptide's half-life?

A half-life is the time it takes for half of a dose to be cleared from circulation. It is a measured pharmacokinetic figure, not a duration of effect: a compound can have left the blood long before its downstream effects have finished, and the two are reported separately in the literature.

Why do some compounds have no sourced half-life here?

Because Prof. Peptide has not found a figure it can attribute. Many research peptides have no published human pharmacokinetic study at all, and a number circulating online trace back to vendor copy rather than to a measurement. A blank row means no citable figure was found, not that the compound clears instantly.

Does half-life tell you how long a peptide stays effective?

No. Half-life describes elimination from plasma. Effect duration depends on receptor binding, downstream signalling and tissue turnover, which can outlast the compound's presence in blood by a wide margin — GHRH analogues are the clearest example, where a half-life of minutes drives a growth-hormone pulse lasting hours.

We may earn commissions from peptide vendor affiliate links.